Literature DB >> 20953847

Advances in prevention of mother-to-child HIV transmission: the international perspectives.

Chokechai Rongkavilit1, Basim I Asmar.   

Abstract

We have sufficient knowledge and unprecedented access to global resources to dramatically reduce the transmission of HIV-1 from mother to children worldwide. Most transmission occurs during delivery and after birth through breastfeeding. For this reason, efforts to interrupt transmission have focused on peripartum period and safe infant feeding. This includes the use of antiretroviral therapy, elective cesarean section, avoidance of breastfeeding, and exclusive breastfeeding. This review summarizes recent studies and new international development on the prevention of mother-to-child HIV transmission. Prevention of mother-to-child transmission of HIV should now be integrated as part of basic maternal and child health services.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20953847     DOI： 10.1007/s12098-010-0258-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  85 in total

1.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  N Shaffer; R Chuachoowong; P A Mock; C Bhadrakom; W Siriwasin; N L Young; T Chotpitayasunondh; S Chearskul; A Roongpisuthipong; P Chinayon; J Karon; T D Mastro; R J Simonds
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

Authors:  K M De Cock; M G Fowler; E Mercier; I de Vincenzi; J Saba; E Hoff; D J Alnwick; M Rogers; N Shaffer
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial.

Authors:  D Mbori-Ngacha; R Nduati; G John; M Reilly; B Richardson; A Mwatha; J Ndinya-Achola; J Bwayo; J Kreiss
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

4.  Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA.

Authors:  K Dominguez; J Bertolli; M Fowler; V Peters; I Ortiz; S Melville; T Rakusan; T Frederick; H Hsu; P D'Almada; Y Maldonado; C Wilfert
Journal:  Ann N Y Acad Sci       Date:  2000-11       Impact factor: 5.691

5.  Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Authors:  R Chuachoowong; N Shaffer; W Siriwasin; P Chaisilwattana; N L Young; P A Mock; S Chearskul; N Waranawat; T Chaowanachan; J Karon; R J Simonds; T D Mastro
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

6.  Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery.

Authors:  Anne Marcollet; François Goffinet; Ghislaine Firtion; Emmanuelle Pannier; Thiphaine Le Bret; Marie-Laure Brival; Laurent Mandelbrot
Journal:  Am J Obstet Gynecol       Date:  2002-04       Impact factor: 8.661

7.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

8.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

9.  Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.

Authors:  Abubaker Bedri; Berhanu Gudetta; Abdulhamid Isehak; Solomon Kumbi; Sileshi Lulseged; Yohannes Mengistu; Arvind V Bhore; Ramesh Bhosale; Venkat Varadhrajan; Nikhil Gupte; Jayagowri Sastry; Nishi Suryavanshi; Srikanth Tripathy; Francis Mmiro; Michael Mubiru; Carolyne Onyango; Adrian Taylor; Philippa Musoke; Clemensia Nakabiito; Aida Abashawl; Rahel Adamu; Gretchen Antelman; Robert C Bollinger; Patricia Bright; Mohammad A Chaudhary; Jacqueline Coberly; Laura Guay; Mary Glenn Fowler; Amita Gupta; Elham Hassen; J Brooks Jackson; Lawrence H Moulton; Uma Nayak; Saad B Omer; Lidia Propper; Malathi Ram; Vivian Rexroad; Andrea J Ruff; Anita Shankar; Sheryl Zwerski
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

10.  Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.

Authors:  Jan Walter; Louise Kuhn; Chipepo Kankasa; Katherine Semrau; Moses Sinkala; Donald M Thea; Grace M Aldrovandi
Journal:  BMC Infect Dis       Date:  2008-12-30       Impact factor: 3.090
View more
  2 in total

1.  Prenatal testing and prevalence of HIV infection during pregnancy: data from the "Birth in Brazil" study, a national hospital-based study.

Authors:  Rosa Maria Soares Madeira Domingues; Celia Landmann Szwarcwald; Paulo Roberto Borges Souza; Maria do Carmo Leal
Journal:  BMC Infect Dis       Date:  2015-02-26       Impact factor: 3.090

2.  Viral Infections During Pregnancy: The Big Challenge Threatening Maternal and Fetal Health.

Authors:  Wenzhe Yu; Xiaoqian Hu; Bin Cao
Journal:  Matern Fetal Med       Date:  2021-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.